Physician

Adit S Mahale, MD

According to 2025 Medicare claims, Adit Mahale, MD (NPI: 1144247750) practices nephrology in the Charlotte-Concord-Gastonia, NC-SC market, with the plurality of this provider's patient population coming from Mecklenburg, NC. This provider's primary affiliated billing organization is METROLINA NEPHROLOGY ASSOCIATES, PA (NPI: 1083664189; TIN: 561378901) and primary practice location at 28208-0014. Mahale is affiliated with the Carolinas HealthCare System ACO, LLC (ACO ID: A3675), participating under the MSSP model.

Mahale's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 516 traditional Medicare patients, billed 7,524 HCPCS/CPT codes, and received $163,562 in Medicare payments. The top billing code was 80197 (Tacrolimus level). Part D data shows 3,201 prescription claims across 511 beneficiaries totaling $337,139 in drug costs, led by Prevymis (Letermovir). DME data shows 2,187 claims. Open Payments data shows 13 records totaling $955. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $221,208 and ending at $337,139. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	660	3,605	$249,727
2016	616	3,167	$211,516
2017	636	3,374	$227,071
2018	868	9,550	$230,207
2019	943	28,460	$325,538
2020	817	16,270	$287,478
2021	782	12,625	$281,065
2022	647	12,110	$216,512
2023	603	10,861	$203,823
2024	516	7,524	$163,562

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	327	2,979	$221,208
2016	334	3,248	$258,900
2017	370	4,310	$278,400
2018	408	3,200	$195,990
2019	436	1,990	$222,541
2020	484	2,854	$281,456
2021	492	2,816	$254,612
2022	415	2,012	$173,579
2023	467	2,394	$486,386
2024	511	3,201	$337,139

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	225	2,123	$158,074
2016	223	2,070	$138,989
2017	241	2,015	$130,965
2018	299	1,817	$115,583
2019	504	1,605	$173,098
2020	827	3,462	$366,736
2021	722	3,213	$332,258
2022	500	2,251	$229,945
2023	486	2,045	$197,586
2024	540	2,187	$193,433

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
80197	Tacrolimus level	241	678	$13
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	233	403	$12
36415	Insertion of needle into vein for collection of blood sample	344	902	$9
80069	Kidney function blood test panel	328	826	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	272	728	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Prevymis	Letermovir	18	490	$133,038
Eliquis	Apixaban	41	1,470	$27,874
Envarsus Xr	Tacrolimus	20	670	$18,091
Cinacalcet Hcl	Cinacalcet Hcl	51	1,943	$17,524
Atovaquone	Atovaquone	41	1,149	$11,687

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	54	247	$148,786
J7518	Mycophenolic acid, oral, 180 mg	N	58	247	$13,552
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	139	463	$8,413
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	147	580	$8,226
J7507	Tacrolimus, immediate release, oral, 1 mg	N	50	208	$5,083

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	13	$955	CALLIDITAS THERAPEUTICS US INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adit S. Mahale, MD?

Tedicare shows public-source Medicare data for Adit S. Mahale, MD (NPI 1144247750), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adit S. Mahale, MD have ACO affiliation data?

Adit S. Mahale, MD is shown with ACO affiliation data for Carolinas HealthCare System ACO, LLC (MSSP, ACO ID A3675).

What billing organization is linked to Adit S. Mahale, MD?

Adit S. Mahale, MD is linked to METROLINA NEPHROLOGY ASSOCIATES, PA (billing NPI 1083664189) in the available physician profile data.

Does Adit S. Mahale, MD have Open Payments data?

Adit S. Mahale, MD has 13 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.